Literature DB >> 8617889

Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12.

A Blauvelt1, C Chougnet, G M Shearer, S I Katz.   

Abstract

Decreased antigen (Ag)-specific T cell (TC) proliferation and IL-2 production are detected in all stages of HIV disease. To determine whether dendritic cell dysfunction and/or abnormal cytokine production contribute to HIV-induced immune dysregulation, we studies TC responses to recall Ags (influenza virus and tetanus toxoid) presented by Langerhans cells (LC) in six pairs of HIV-discordant identical twins, and the modulation of these responses by anti-IL-10 (alphaIL-10) mAbs and IL-12. LC from HIV+ twins induced IL-2 comparable to normal LC in cultures containing TC from uninfected twins. In contrast, IL-2 production was markedly decreased in cultures containing TC from HIV+ twins. IL-12 enhanced Ag-specific IL-2 production by TC from two patients with CD4+ counts > 600. In contrast, alphaIL-10 mAbs enhanced IL-2 production in influenza virus-stimulated cultures containing TC from two patients with CD4+ counts < 20. Thus, these findings suggest that immunologic dysfunction of dendritic cells does not contribute to impaired secondary immune responses in HIV+ individuals. Although few patients were studied, partial immune reconstitution in vitro, as demonstrated here, may help to predict those individuals who might benefit from cytokines or antibodies against cytokines as immunotherapy for HIV disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617889      PMCID: PMC507216          DOI: 10.1172/JCI118578

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Epidermal langerhans cells of AIDS patients express HIV-1 regulatory and structural genes.

Authors:  M Henry; A Uthman; C Ballaun; G Stingl; E Tschachler
Journal:  J Invest Dermatol       Date:  1994-10       Impact factor: 8.551

2.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.

Authors:  N Bhardwaj; A Bender; N Gonzalez; L K Bui; M C Garrett; R M Steinman
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 3.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.

Authors:  G Trinchieri
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

4.  Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection.

Authors:  L Meyaard; S A Otto; I P Keet; R A van Lier; F Miedema
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

5.  Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages.

Authors:  N A Kootstra; A van 't Wout; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

6.  Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1.

Authors:  M Pope; M G Betjes; N Romani; H Hirmand; P U Cameron; L Hoffman; S Gezelter; G Schuler; R M Steinman
Journal:  Cell       Date:  1994-08-12       Impact factor: 41.582

7.  T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection.

Authors:  M Zhang; J Gong; D V Iyer; B E Jones; R L Modlin; P F Barnes
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

8.  IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages.

Authors:  R E Akridge; L K Oyafuso; S G Reed
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

9.  Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro.

Authors:  L J Montaner; P Griffin; S Gordon
Journal:  J Gen Virol       Date:  1994-12       Impact factor: 3.891

10.  Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.

Authors:  M Matsuda; F Salazar; M Petersson; G Masucci; J Hansson; P Pisa; Q J Zhang; M G Masucci; R Kiessling
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.

Authors:  Ling Shao; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 2.  Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection.

Authors:  D Weissman; A S Fauci
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  The Role of Antigen-presenting Cells in HIV Pathogenesis.

Authors:  Claire Chougnet; Gene M. Shearer; Alan L. Landay
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

4.  Early cytokine and chemokine gene expression in lymph nodes of macaques infected with simian immunodeficiency virus is predictive of disease outcome and vaccine efficacy.

Authors:  W Zou; A A Lackner; M Simon; I Durand-Gasselin; P Galanaud; R C Desrosiers; D Emilie
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

5.  Impaired accessory cell function in a human dendritic cell line after human immunodeficiency virus infection.

Authors:  Prarthana Beuria; Houchu Chen; Michael Timoney; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

6.  Preserved MHC class II antigen processing in monocytes from HIV-infected individuals.

Authors:  Laila Woc-Colburn; Lavinia Smultea; Lakshmi Ramachandra; David H Canaday
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

7.  Cytokine response in multiple lymphoid tissues during the primary phase of feline immunodeficiency virus infection.

Authors:  G A Dean; N C Pedersen
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.